Imaavy Label Lists gMG Treatment for Patients Age 12+

The U.S. Food and Drug Administration updated the IMAAVY label for nipocalimab on August 21, 2026. The revised Indications and Usage section identified IMAAVY as a treatment for generalized myasthenia gravis, or gMG, in adult and pediatric patients 12 years of age and older. The supplied label summary also specified patients who are anti-acetylcholine receptor, or AChR, antibody-positive, along with another patient category whose wording was truncated in the available record.

Background

IMAAVY is the brand name listed for nipocalimab. The FDA label described it as a neonatal Fc receptor blocker. The updated indication concerned generalized myasthenia gravis and included both adults and pediatric patients beginning at age 12. The supplied data did not provide additional information about the drug’s mechanism, dosing, administration, clinical-trial evidence, safety findings, or earlier labeling.

What changed

The event was classified as an FDA label revision affecting Indications and Usage. The available summary stated: “IMAAVY is a neonatal Fc receptor blocker indicated for the treatment of: generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or ant…” Because the source excerpt ended after “ant,” the supplied record does not establish the complete second antibody or patient-group description.

This revision therefore supports reporting the age range, disease indication, drug identity, and anti-AChR wording shown in the supplied label summary. It does not support adding a complete eligibility statement beyond the text provided, or drawing conclusions about comparative effectiveness or safety.

What this means

For clinicians and researchers, the key labeling information is that the IMAAVY indication covered gMG patients aged 12 years and older, including adults and pediatric patients, with the supplied summary identifying anti-AChR status as part of the stated population. Patient advocates and reference editors should consult the full DailyMed label for the complete sentence and current prescribing details, because the event record provided only a truncated indication excerpt.

Source

Source: FDA, IMAAVY prescribing-label record, indication and usage revision effective August 21, 2026. The document is hosted at dailymed.nlm.nih.gov and is available at dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8886274c-f2b2-48af-85c1-2f90bfe304b8.